shares

View All

Therapeutics
Letter for AstraZeneca; Patheon on API plant; Sanofi, Regeneron’s Dupixent; Cerulean Pharma and Daré Bioscience enter into deal; Lilly on price hikes

AstraZeneca slapped with second Complete Response Letter Having a potential blockbuster sidelined because of manufacturing issues is bad enough, but AstraZeneca has now had that experience twice—both times receiving a complete response letter from the FDA. For a second time, AstraZeneca has received a complete respo...

Find More